Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...
Inito has raised $29 million in new funding to invest in and develop AI-engineered antibodies that will help it offer new types of tests and improve the accuracy of existing ones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback